Multiple Sclerosis
Conditions
Brief summary
Inclusion visit (D0): * verification of inclusion and non-inclusion criteria * information and collection of consent * standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), o 3D STIR sequence. * 3D PSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 45 minutes (instead of 35 minutes).
Interventions
* standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), o 3D STIR sequence. * 3D PSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 45 minutes (instead of 35 minutes)
Sponsors
Study design
Eligibility
Inclusion criteria
* Patient over 18 years old * To benefit from a medullary exploration planned by MRI 1.5T as part of a first evaluation or a re-evaluation of inflammatory involvement of the nevrax * Express consent to participate in the study * Affiliate or beneficiary of a social security scheme
Exclusion criteria
* Patient benefiting from a legal protection measure * Pregnant, parturient or breastfeeding woman * Absolute or relative contraindication to MRI
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estimate the number of spinal cord injuries detected with the set of standard sequences (T1, T2 and STIR) that are not detected with the 3D PSIR sequence | 1 DAY |
| Estimate the number of active lesions taking the contrast after injection of gadolinium, with the 3D PSIR sequence which is not detected in the set of standard sequences (T1, T2 and STIR) | 1 day |
| Compare the diagnostic confidence expressed by the radiologist for the detection of spinal cord injuries with the 3D PSIR sequence compared to the set of standard sequences (T1, T2 and STIR) | 1 DAY |
| Describe the quality of the images in terms of artifacts for each of the sequences used (T1, T2, STIR and PSIR) | 1 DAY |
| Measure the signal-to-noise ratio of each of the sequences used (T1, T2, STIR and PSIR) | 1 DAY |
| Measure the inter-observer agreement on the number of lesions detected with the 3D PSIR sequence | 1 DAY |
| Measure the intra-observer agreement on the number of lesions detected with the 3D PSIR sequence | 1 DAY |
Countries
France